RATIONALE: The rate of annual change in FEV1 is highly variable among patients with chronic obstructive pulmonary disease (COPD). Reliable blood biomarkers are needed to predict prognosis. OBJECTIVES: To explore plasma biomarkers associated with an annual change in FEV1 in patients with COPD. METHODS: Plasma samples of 261 subjects, all Japanese, with COPD from the 5-year Hokkaido COPD cohort study were analyzed as a hypothesis-generating cohort, and the results were validated using data of 226 subjects with and 268 subjects without airflow limitation, mainly white, from the 4-year COPD Quantification by Computed Tomography, Biomarkers, and Quality of Life (CBQ) study conducted in Denmark. The plasma samples were measured using Human CardiovascularMAP (Myriad RBM, Austin, TX), which could analyze 50 biomarkers potentially linked with inflammatory, metabolic, and tissue remodeling pathways, and single ELISAs were used to confirm the results. MEASUREMENTS AND MAIN RESULTS: Higher plasma adiponectin levels and a lower leptin/adiponectin ratio at enrollment were significantly associated with an annual decline in FEV1 even after controlling for age, sex, height, and body mass index in the Hokkaido COPD cohort study (P = 0.003, P = 0.004, respectively). A lower plasma leptin/adiponectin ratio was also significantly associated with an annual decline in FEV1 in subjects with airflow limitation in the CBQ study (P = 0.014), the patients of which had largely different clinical characteristics compared with the Hokkaido COPD cohort study. There were no significant associations between lung function decline and adipokine levels in subjects without airflow limitation. CONCLUSIONS: A lower leptin/adiponectin ratio was associated with lung function decline in patients with COPD in two independent Japanese and Western cohort studies of populations of different ethnicity. Measure of systemic adipokines may provide utility in predicting patients with COPD at higher risk of lung function decline.
RATIONALE: The rate of annual change in FEV1 is highly variable among patients with chronic obstructive pulmonary disease (COPD). Reliable blood biomarkers are needed to predict prognosis. OBJECTIVES: To explore plasma biomarkers associated with an annual change in FEV1 in patients with COPD. METHODS: Plasma samples of 261 subjects, all Japanese, with COPD from the 5-year Hokkaido COPD cohort study were analyzed as a hypothesis-generating cohort, and the results were validated using data of 226 subjects with and 268 subjects without airflow limitation, mainly white, from the 4-year COPD Quantification by Computed Tomography, Biomarkers, and Quality of Life (CBQ) study conducted in Denmark. The plasma samples were measured using Human CardiovascularMAP (Myriad RBM, Austin, TX), which could analyze 50 biomarkers potentially linked with inflammatory, metabolic, and tissue remodeling pathways, and single ELISAs were used to confirm the results. MEASUREMENTS AND MAIN RESULTS: Higher plasma adiponectin levels and a lower leptin/adiponectin ratio at enrollment were significantly associated with an annual decline in FEV1 even after controlling for age, sex, height, and body mass index in the Hokkaido COPD cohort study (P = 0.003, P = 0.004, respectively). A lower plasma leptin/adiponectin ratio was also significantly associated with an annual decline in FEV1 in subjects with airflow limitation in the CBQ study (P = 0.014), the patients of which had largely different clinical characteristics compared with the Hokkaido COPD cohort study. There were no significant associations between lung function decline and adipokine levels in subjects without airflow limitation. CONCLUSIONS: A lower leptin/adiponectin ratio was associated with lung function decline in patients with COPD in two independent Japanese and Western cohort studies of populations of different ethnicity. Measure of systemic adipokines may provide utility in predicting patients with COPD at higher risk of lung function decline.
Authors: Tatsiana Beiko; Michael G Janech; Alexander V Alekseyenko; Carl Atkinson; Harvey O Coxson; Jeremy L Barth; Sarah E Stephenson; Carole L Wilson; Lynn M Schnapp; Alan Barker; Mark Brantly; Robert A Sandhaus; Edwin K Silverman; James K Stoller; Bruce Trapnell; Strange Charlie Journal: Chronic Obstr Pulm Dis Date: 2017-07-15
Authors: Eric Garshick; Palak Walia; Rebekah L Goldstein; Merilee Teylan; Antonio A Lazzari; Carlos G Tun; Jaime E Hart Journal: PM R Date: 2017-08-19 Impact factor: 2.298
Authors: Young Ju Suh; Merry-Lynn N McDonald; George R Washko; Brendan J Carolan; Russell P Bowler; David A Lynch; Gregory L Kinney; Jessica M Bon; Michael H Cho; James D Crapo; Elizabeth A Regan Journal: Chronic Obstr Pulm Dis Date: 2018-04-01
Authors: Qiuying Chen; Ruba S Deeb; Yuliang Ma; Michelle R Staudt; Ronald G Crystal; Steven S Gross Journal: PLoS One Date: 2015-12-16 Impact factor: 3.240